Utilities around the world have been considering Demand Side Management (DSM) in their strategic planning. The costs of constructing and operating a new capacity generation unit are increasing everyday as well as Tran...Utilities around the world have been considering Demand Side Management (DSM) in their strategic planning. The costs of constructing and operating a new capacity generation unit are increasing everyday as well as Transmission and distribution and land issues for new generation plants, which force the utilities to search for another alternatives without any additional constraints on customers comfort level or quality of delivered product. De can be defined as the selection, planning, and implementation of measures intended to have an influence on the demand or customer-side of the electric meter, either caused directly or stimulated indirectly by the utility. DSM programs are peak clipping, Valley filling, Load shifting, Load building, energy conservation and flexible load shape. The main Target of this paper is to show the relation between DSM and Load Forecasting. Moreover, it highlights on the effect of applying DSM on Forecasted demands and how this affects the planning strategies for utility companies. This target will be clearly illustrated through applying the developed algorithm in this paper on an existing residential compound in Cairo-Egypt.展开更多
BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have been adopted as the standard of care for non-small cell lung cancer(NSCLC)patients harboring EGFR sensitizing mutations.Besides the...BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have been adopted as the standard of care for non-small cell lung cancer(NSCLC)patients harboring EGFR sensitizing mutations.Besides the two common mutations exon 19 deletion and L858R,which together comprise approximately 85%of EGFR mutations in NSCLC,rare EGFR mutations also exist,including point mutations,deletions,and insertions spanning EGFR exons 18-25.However,the responsiveness of uncommon EGFR mutations to EGFR TKIs remains elusive and attracts increasing interest.CASE SUMMARY Herein,we report a 55-year-old male patient with stage IV NSCLC harboring a rare EGFR L833F-L861Q compound mutation in cis.The patient achieved a partial response to first-line treatment with afatinib and a progression-free survival of 10 mo.After afatinib failure,the patient received multiple line treatments with chemotherapy.Upon disease progression,the heavily pretreated patient was treated with osimertinib and bevacizumab,and both lung lesion and brain metastases were stable for more than 3 mo.He had an overall survival of 25 mo.CONCLUSION Our case revealed that both afatinib and the osimertinib+bevacizumab combination demonstrated clinical efficacy in NSCLC harboring an EGFR L833FL861Q compound mutation.The results provide more therapeutic options for patients with rare compound mutations.展开更多
文摘Utilities around the world have been considering Demand Side Management (DSM) in their strategic planning. The costs of constructing and operating a new capacity generation unit are increasing everyday as well as Transmission and distribution and land issues for new generation plants, which force the utilities to search for another alternatives without any additional constraints on customers comfort level or quality of delivered product. De can be defined as the selection, planning, and implementation of measures intended to have an influence on the demand or customer-side of the electric meter, either caused directly or stimulated indirectly by the utility. DSM programs are peak clipping, Valley filling, Load shifting, Load building, energy conservation and flexible load shape. The main Target of this paper is to show the relation between DSM and Load Forecasting. Moreover, it highlights on the effect of applying DSM on Forecasted demands and how this affects the planning strategies for utility companies. This target will be clearly illustrated through applying the developed algorithm in this paper on an existing residential compound in Cairo-Egypt.
文摘BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have been adopted as the standard of care for non-small cell lung cancer(NSCLC)patients harboring EGFR sensitizing mutations.Besides the two common mutations exon 19 deletion and L858R,which together comprise approximately 85%of EGFR mutations in NSCLC,rare EGFR mutations also exist,including point mutations,deletions,and insertions spanning EGFR exons 18-25.However,the responsiveness of uncommon EGFR mutations to EGFR TKIs remains elusive and attracts increasing interest.CASE SUMMARY Herein,we report a 55-year-old male patient with stage IV NSCLC harboring a rare EGFR L833F-L861Q compound mutation in cis.The patient achieved a partial response to first-line treatment with afatinib and a progression-free survival of 10 mo.After afatinib failure,the patient received multiple line treatments with chemotherapy.Upon disease progression,the heavily pretreated patient was treated with osimertinib and bevacizumab,and both lung lesion and brain metastases were stable for more than 3 mo.He had an overall survival of 25 mo.CONCLUSION Our case revealed that both afatinib and the osimertinib+bevacizumab combination demonstrated clinical efficacy in NSCLC harboring an EGFR L833FL861Q compound mutation.The results provide more therapeutic options for patients with rare compound mutations.
